Stem cell transplant 'preferred option' in multiple myeloma treatment

18 May 2016

Stem cell transplant should remain the preferred treatment for patients with multiple myeloma aged 65 and under, according to a new study.

Early findings from a randomized Phase III trial of 1,266 patients who were newly-diagnosed with the rare blood cancer showed that those who received an autologous stem cell transplant (ASCT) survived longer without disease progression than those who received only chemotherapy using novel agents.

It is the largest study reported to date aimed at comparing ASCT with a bortezomib-based regimen alone in patients younger than 65. The results of the study are due to be presented at the 2016 American Society of Clinical Oncology (ASCO), being held in Chicago next month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK